Anti-inflammatories
This article was originally published in The Tan Sheet
Executive Summary
Active recruitment for Alzheimer's Disease Anti-inflammatory Prevention Trial began Jan. 30; target enrollment is 2,625 adults over age 70. The National Institute on Aging-sponsored trial will compare effects of Bayer's Aleve (naproxen sodium), Searle/Pfizer's Rx COX-2 Celebrex (celecoxib) and placebo on age-related memory loss among healthy participants with a family history of dementia or Alzheimer's. The four-center, seven-year trial headed by John Breitner, MD, Johns Hopkins School of Hygiene & Public Health, resembles another NIA trial investigating effects of Merck's Vioxx and Aleve on cognitive decline in Alzheimer's patients; the latter trial hopes to produce results by 2002 (1"The Tan Sheet" Feb. 21, 2000, p. 13)
You may also be interested in...
NSAID Use For Alzheimer’s Prevention Future Research Suggested In JAMA
Future research on non-steroidal anti-inflammatory drugs and Alzheimer's disease may need to focus on prevention rather than treatment, an editorial in the June 4 Journal of the American Medical Association suggests
NIA Aleve Vs. Vioxx Alzheimer's Study To Produce Data By 2002
A National Institute on Aging study comparing Bayer's OTC Aleve and Merck's Rx Vioxx in Alzheimer's patients will produce data in two and a half years.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC